US 12,152,023 B2
Compositions, formulations and methods for treating ocular diseases
Kevin Peters, Cincinnati, OH (US); Robert Shalwitz, Bexley, OH (US); John Janusz, West Chester, OH (US); and Alexander Smith, Apex, NC (US)
Assigned to EYEPOINT PHARMACEUTICALS, INC., Watertown, MA (US)
Filed by EyePoint Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Mar. 3, 2022, as Appl. No. 17/685,802.
Application 17/685,802 is a continuation of application No. 16/888,247, filed on May 29, 2020, abandoned.
Application 16/888,247 is a continuation of application No. 15/958,358, filed on Apr. 20, 2018, abandoned.
Application 15/958,358 is a continuation of application No. 15/443,622, filed on Feb. 27, 2017, abandoned.
Application 15/443,622 is a continuation of application No. 15/098,955, filed on Apr. 14, 2016, abandoned.
Application 15/098,955 is a continuation of application No. 13/999,670, filed on Mar. 14, 2014, granted, now 9,440,963, issued on Sep. 13, 2016.
Claims priority of provisional application 61/934,570, filed on Jan. 31, 2014.
Claims priority of provisional application 61/882,048, filed on Sep. 25, 2013.
Claims priority of provisional application 61/882,056, filed on Sep. 25, 2013.
Claims priority of provisional application 61/792,679, filed on Mar. 15, 2013.
Claims priority of provisional application 61/792,868, filed on Mar. 15, 2013.
Prior Publication US 2022/0274976 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/433 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/538 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61K 47/69 (2017.01); A61P 27/00 (2006.01); A61P 27/02 (2006.01); C07D 277/28 (2006.01); C07D 277/30 (2006.01); C07D 277/56 (2006.01); C07D 277/60 (2006.01); C07D 277/64 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)
CPC C07D 417/12 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0051 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/538 (2013.01); A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61K 47/6951 (2017.08); A61P 27/00 (2018.01); A61P 27/02 (2018.01); C07D 277/28 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 277/60 (2013.01); C07D 277/64 (2013.01); C07D 417/04 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01)] 18 Claims
 
1. A method for reducing central retinal thickness in a subject in need thereof, comprising:
administering to the subject a pharmaceutical composition comprising a therapeutically-effective amount of a Tie-2 activator; and
administering to the subject a therapeutically-effective amount of an anti-VEGF agent, wherein the Tie-2 activator is a compound of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically-acceptable salt or zwitterion thereof.